PCN3 Quality-Adjusted Survival in Patients With Wild-Type (WT) KRASs Metastatic Colorectal Cancer (mCRC) Receiving First-Line Therapy With Panitumumab Plus FOLFOX Versus FOLFOX Alone

J. Wang, Jean‐Yves Douillard, Beth Sherrill et al.|Value in Health|2012

Cited by 0